The Feasibility of Utilizing Plasma &lt;em&gt;MiRNA107&lt;/em&gt; and &lt;em&gt;BACE1&lt;/em&gt; Messenger RNA Gene Expression for Clinical Diagnosis of Amnestic Mild Cognitive Impairment

Wang, Tao; Chen, Kewei; Li, Huafang; Dong, Shu-Hui; Su, Ning; Liu, Yuanyuan; Cheng, Yan; Dai, Jing; Yang, Cuiwei; Xiao, Shifu

doi:10.4088/jcp.13m08812

Cited by 45 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The verification experiment indicated 6 miRNAs as the best candidates for further verification in larger cohorts as possible early AD biomarkers. References: * [20–46, 57, 84–87], # [21, 22, 28, 30, 57, 87]. …”

Section: Resultsmentioning

confidence: 99%

“…The source of miRNAs is another important aspect. So far different blood sources were investigated for detection of circulating miRNAs in AD patients: plasma [21, 31, 34, 35, 38, 46, 87], serum [20, 24, 25, 27, 32, 33, 36, 40–43], blood mononuclear cells [30], whole blood [22, 84–86] and plasma exosomes [29]. All miRNA sources have some advantages and disadvantages.…”

Section: Discussionmentioning

confidence: 99%

“…Based on exclusion criteria (review, conference articles and animal model studies), and based on inclusion criteria (only microRNA studies in whole blood, blood cells, plasma and serum) 31 articles were found to be eligible to perform comparative analysis with our stage 1 results [20–46, 84–87]. …”

Section: Methodsmentioning

confidence: 99%

“…For AD, so far 31 investigations indicated potential for miRNAs as biomarkers in the blood (serum, plasma, blood cells, and whole blood were analyzed) [20–46, 84–87]. However, broader reproducibility of the results has not yet been achieved, which is currently seen as, to a high degree, the result of substantial variability across various diagnostic centers in pre-analytical, analytical and post-analytical factors, referring to both the diagnosis of patients recruited for studies, and to the methodology of blood handling and miRNA analysis [47, 48].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

et al. 2017

View full text Add to dashboard Cite

Alzheimers disease (AD) is the most common age-related dementia. Among its major challenges is identifying molecular signatures characteristic for the early AD stage in patients with Mild Cognitive Impairment (MCI-AD), which could serve for deciphering the AD pathomechanism and also as non-invasive, easy-to-access biomarkers. Using qRT-PCR we compared the microRNA (miRNA) profiles in blood plasma of 15 MCI-AD patients, whose diagnoses were confirmed by cerebrospinal fluid (CSF) biomarkers, with 20 AD patients and 15 non-demented, age-matched individuals (CTR).To minimize methodological variability, we adhered to standardization of blood and CSF assays recommended by the international Joint Programming for Neurodegenerative Diseases (JPND) BIOMARKAPD consortium, and we employed commercially available Exiqon qRT-PCR-assays. In the first screening, we assessed 179 miRNAs of plasma. We confirmed 23 miRNAs reported earlier as AD biomarker candidates in blood and found 26 novel differential miRNAs between AD and control subjects. For representative 15 differential miRNAs, the TargetScan, MirTarBase and KEGG database analysis indicated putative protein targets among such AD hallmarks as MAPT (Tau), proteins involved in amyloidogenic proteolysis, and in apoptosis. These 15 miRNAs were verified in separate, subsequent subject groups. Finally, 6 miRNAs (3 not yet reported in AD context and 3 reported in AD blood) were selected as the most promising biomarker candidates differentiating early AD from controls with the highest fold changes (from 1.32 to 14.72), consistent significance, specificities from 0.78 to 1 and sensitivities from 0.75 to 1. (patent pending, PCT/IB2016/052440).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

et al. 2017

View full text Add to dashboard Cite

show abstract

“…They exhibit high stability in plasma, serum, urine and saliva (Chen et al, 2008), and can be detected as cell-free or exosome-derived molecules (Mitchell et al, 2008). Recent studies have shown that in CNS diseases such as stroke, Alzheimer’s disease (AD) and glioblastoma, the pathological processes in the brain could be reflected in peripheral miRNA expression patterns (Zeng et al, 2011; Ilhan-Mutlu et al, 2012; Rao et al, 2013; Wang et al, 2015). Thus, plasma miRNA expression levels in PD patients may help us understand the pathological processes in the brains as those aforementioned diseases.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-4639 Is a Regulator of DJ-1 Expression and a Potential Early Diagnostic Marker for Parkinson’s Disease

Chen

Gao

Sun

et al. 2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and has profound impacts on the daily lives of patients. However, there is a lack of effective biomarkers for early diagnosis, and the mechanisms of PD pathogenesis remain obscure. microRNAs (miRNAs) are post-transcriptional gene regulators and can be easily detected in plasma, which suggests a promising role as diagnostic markers. Here, we aimed to explore a peripheral biomarker, which not only can be applied for early diagnosis of PD but also has the potential to be a therapeutic target. Through miRNA microarray screening and further validation in plasma from 169 sporadic PD patients, 170 healthy controls, and 60 essential tremor (ET) patients, hsa-miR-4639-5p level was identified to be significantly up-regulated in PD patients. Also, it was able to discriminate between early PD patients (disease duration ≤2 years or Hoehn and Yahr stage 1–2.5) and healthy controls. Furthermore, hsa-miR-4639-5p was shown to negatively regulate DJ-1 (PARK7), a well-known PD-related gene, in the post-transcriptional level. Abnormal up-regulation of hsa-miR-4639-5p caused down-regulation of DJ-1 protein level, leading to severe oxidative stress and neuronal death. In conclusion, hsa-miR-4639-5p has the potential to be a peripheral diagnostic biomarker and therapeutic target for early PD.

show abstract

Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training

Sousa

Improta-Caria

2022

Metab Brain Dis

View full text Add to dashboard Cite

The Feasibility of Utilizing Plasma <em>MiRNA107</em> and <em>BACE1</em> Messenger RNA Gene Expression for Clinical Diagnosis of Amnestic Mild Cognitive Impairment

Abstract: ClinicalTrials.gov identifier: NCT01819545.

Cited by 45 publications

References 34 publications

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

MicroRNA-4639 Is a Regulator of DJ-1 Expression and a Potential Early Diagnostic Marker for Parkinson’s Disease

Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training

Contact Info

Product

Resources

About